Peakexplorer 4 launched

Peakdale Molecular has launched its fourth Peakexplorer GPCR (G-protein coupled receptor) library featuring more than 1,100 compounds specifically designed, synthesised and characterised for screening against GPCR targets.

This latest library has been created through the assessment of seven chemotypes intended to target GPCRs and includes a novel, proprietary Peakdale chemotype specifically designed to take advantage of the Company's aminergic GPCR pharmacophore know-how.

Peakdale's four Peakexplorer GPCR libraries have been created through a novel process that combines in silico pharmacophore modelling with design and virtual screening algorithms to create novel drug-like compounds.

Ray Fisher, Peakdale's, commercial director, explained: 'Our customers have commented that the Peakexplorer sets correlate well with data from their virtual screening programmes, providing a rich source of novel screening compounds to fill gaps in their own collections of compounds. And the quality of our earlier libraries has already been demonstrated by customers now making repeat purchases to confirm their early hits.'

The full Peakexplorer GPCR library now exploits over 19 major chemotypes and offers more than 5,000 drug-like compounds that have been purified, characterised and are ready for screening. Peakdale operates a fully flexible despatch process allowing customers to request compounds in their preferred format, for example 20mg in barcoded vials or 10mM DMSO solution in 384-well plates.